IMTXImmatics N.V.

Nasdaq immatics.com


$ 12.95 $ -0.17 (-1.3 %)    

Thursday, 13-Jun-2024 15:59:55 EDT
QQQ $ 476.97 $ 2.57 (0.54 %)
DIA $ 386.89 $ -0.81 (-0.21 %)
SPY $ 542.45 $ 1.09 (0.2 %)
TLT $ 93.85 $ 1.36 (1.47 %)
GLD $ 212.97 $ -1.75 (-0.82 %)
$ 12.95
$ 13.05
$ 12.92 x 200
$ 12.95 x 139
$ 12.84 - $ 13.22
$ 7.15 - $ 13.77
249,452
na
1.1B
$ 0.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mizuho-maintains-buy-on-immatics-raises-price-target-to-16

Mizuho analyst Graig Suvannavejh maintains Immatics (NASDAQ:IMTX) with a Buy and raises the price target from $14 to $16.

 immatics-prices-175m-public-offering-of-15925000-ordinary-shares-at-11share

he gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be appro...

 cantor-fitzgerald-initiates-coverage-on-immatics-with-overweight-rating

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Immatics (NASDAQ:IMTX) with a Overweight rating.

Core News & Articles

Moderna, Inc. (NASDAQ:MRNA, &ldquo, Moderna&rdquo, )) and Immatics N.V. (NASDAQ:IMTX, &ldquo, Immatics&rdquo, )...

 immatics-q2-eps-035-misses-024-estimate-sales-2436m-beat-1893m-estimate

Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.24) by...

 why-immatics-shares-are-rising-today

Immatics N.V. (NASDAQ: IMTX) shares are trading higher after the company announced 

 immatics-biotechnologies-granted-us-patent-11685769-peptides-for-use-in-immunotherapy-against-cancers

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11685769

 top-5-health-care-stocks-that-may-crash-this-month

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

 immatics-biotechnologies-granted-us-patent-11673917--peptides-combination-of-peptides-and-cell-based-medicaments-for-use-in-immunotherapy-against-urinary-bladder-cancer-and-other-cancers

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11673917

 recap-immatics-q1-earnings
Recap: Immatics Q1 Earnings
05/16/2023 13:25:09

 immatics-biotechnologies--granted-us-patent-11648276--immunotherapy-against-neuronal-and-brain-tumors-11648292--immunotherapy-against-several-tumors-including-gastrointestinal-and-gastric-cancer

 US 11648276 B2    Abstract The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic m...